Thermo Fisher Scientific (NYSE:TMO) Hits New 12-Month High After Earnings Beat

Key Points

• Thermo Fisher Scientific exceeded quarterly expectations: Revenue rose 9.1% year over year to $12.14 billion, while EPS of $6.68 surpassed the $6.40 consensus estimate.
• Shares reached a new 52-week high of $705.79 following the earnings beat, despite initial trading volatility.
• Management raised its 2026 outlook, lifting its organic revenue-growth forecast to 4% as improving customer activity and expanded operating margins supported the recovery.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s stock price reached a new 52-week high on Thursday following a better than expected earnings announcement. The stock traded as high as $705.79 and last traded at $693.9840, with a volume of 4,049,061 shares trading hands. The stock had previously closed at $687.37.

The medical research company reported $6.68 EPS for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $12.14 billion during the quarter, compared to analysts' expectations of $11.95 billion. During the same period in the prior year, the company earned $5.79 EPS. The business's quarterly revenue was up 9.1% compared to the same quarter last year.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Quarterly results exceeded expectations. Thermo Fisher reported revenue of $12.14 billion, up 9% year over year and above the roughly $11.95 billion consensus estimate. Adjusted EPS rose 15% to $6.68, beating expectations of $6.40. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Organic growth and margins improved. Organic revenue growth reached 6%, driven by stronger customer activity in clinical research, bioproduction and laboratory products. Operating margin expanded to 24.5%, aided by process improvements, acquisitions and divestitures. Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore
• Positive Sentiment: Management raised its full-year outlook. Thermo Fisher lifted its 2026 organic revenue-growth forecast to 4% while increasing full-year earnings and revenue guidance, reinforcing expectations for continued recovery. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Trading was volatile: despite the earnings beat, shares initially fell in premarket trading before reversing higher. This suggests some investors may have been seeking an even stronger outlook or were taking profits after the recent rally. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Unusually high put-option activity indicates that some traders were positioned defensively, although this does not necessarily reflect the company’s fundamentals.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent research reports. Guggenheim assumed coverage on Thermo Fisher Scientific in a research report on Thursday, October 15th. They set a "buy" rating on the stock. Jefferies Financial Group restated a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Citigroup cut Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a report on Wednesday, September 9th. CLSA began coverage on Thermo Fisher Scientific in a research report on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 price objective on the stock. Finally, Royal Bank Of Canada set a $740.00 target price on Thermo Fisher Scientific in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $657.57.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares of the company's stock, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,768 shares of company stock worth $44,122,820 over the last ninety days. Corporate insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Strengthening Families & Communities LLC boosted its holdings in Thermo Fisher Scientific by 0.4% in the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company's stock valued at $3,187,000 after purchasing an additional 21 shares during the period. Bell Bank lifted its holdings in shares of Thermo Fisher Scientific by 10.8% during the 3rd quarter. Bell Bank now owns 624 shares of the medical research company's stock worth $421,000 after acquiring an additional 61 shares during the period. 55 North Private Wealth LLC boosted its position in shares of Thermo Fisher Scientific by 40.9% during the 3rd quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company's stock worth $612,000 after acquiring an additional 263 shares in the last quarter. Jeppson Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $213,000. Finally, James Hambro & Partners LLP increased its stake in Thermo Fisher Scientific by 0.8% in the third quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company's stock valued at $156,260,000 after acquiring an additional 1,919 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

The firm has a market capitalization of $256.60 billion, a P/E ratio of 28.84, a PEG ratio of 2.87 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The business's 50 day moving average is $642.42 and its 200-day moving average is $552.67.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.